Retatrutide, a novel dual agonist of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor , is exhibiting promising outcomes in initial human studies. Recent inquiry suggests https://bookmarkshut.com/story22948673/retatrutide-emerging-research-and-potential-medical-uses